Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Sec14L6 Is a Phosphoinositide Transporter That Regulates Phosphoinositide Homeostasis and Biogenesis of Lipid Droplet

Ji W., zhou T., hu x., Xiong J., Du Y.

Animal Study on Face & Skin, published in (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
(2025)
Reported sample size
—
Source database
Europe PMC
PMID
41298368
PMCID
PMC12658205
DOI
10.21203/rs.3.rs-6888955/v1
Citations
2

Abstract (original English)

Abstract Lipid droplets (LDs) are evolutionarily conserved organelles crucial for cellular metabolism. Their biogenesis and growth occur in the endoplasmic reticulum (ER) and rely on lipid transfer between the ER and LDs. However, the molecular mechanisms remain poorly understood. In this study, we identified Sec14L6, a unique Sec14 protein family member, as a lipid transporter that regulates phosphoinositide homeostasis and biogenesis of LDs, and is required for the differentiation of adipose-derived mesenchymal stem cells. Sec14L6 directly binds to ACSL3, a known LD biogenesis factor, which facilitates the association of Sec14L6 with LD surface. Furthermore, we identify PGRMC1, an ER membrane protein, as an adaptor that recruits Sec14L6 to the ER, specifying a role for Sec14L6 at ER-LD interface. Targeted lipidomics revealed profound dysregulation of PIP homeostasis: residual LDs from Sec14L6-KO cells exhibited aberrant accumulation of PI4P and PI(4,5)P2, concomitant with a reduction of these PIPs within the ER compartment. In vitro assays demonstrate that Sec14L6 preferentially transports phosphoinositide-4-phosphate (PI4P) and PI(4,5)P2. Sec14L6 knockout (KO) severely impaired nascent LD formation, a defect rescued by wild-type Sec14L6 but not by lipid-transfer-deficient mutants. Our study identified Sec14L6 as a new factor that regulates PIP homeostasis and biogenesis of L

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Endoplasmic ReticulumMesenchymal Stem CellsAnimalsHumansMiceCoenzyme A LigasesPhosphatidylinositolsPhosphatidylinositol PhosphatesPhosphatidylinositol 4,5-DiphosphateMembrane Proteins

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research